The IL-23 inhibitor from AbbVie indicated for the treatment of adults with
active psoriatic arthritis (PsA) and for moderate to severe plaque psoriasis (Ps)
in adults who are candidates for systemic therapy or phototherapy.1

SKYRIZI VS OTEZLA® (apremilast)
SKYRIZI VS COSENTYX® (secukinumab)
SKYRIZI VS HUMIRA® (adalimumab)
SKYRIZI VS STELARA® (ustekinumab)
Woman in a blue dress smiles

SKYRIZI VS HUMIRA® (adalimumab)2

SUPERIOR RATES OF PASI 90 AT WEEK 16 IN A PHASE 3,
RANDOMIZED, DOUBLE-BLIND STUDY OF PATIENTS WITH Ps

CO-PRIMARY ENDPOINTS IN ULTIMMA-1 AND ULTIMMA-2 (NRI)1,3

PASI 90 at Week 16
UltIMMa-1:
SKYRIZI 75% (229/304), placebo 5% (5/102)
UltIMMa-2:
SKYRIZI 75% (220/294), placebo 2% (2/98)

P<0.0001.

sPGA 0/1 at Week 16
UltIMMa-1:
SKYRIZI 88% (267/304), placebo 8% (8/102)
UltIMMa-2:
SKYRIZI 84% (246/294), placebo 5% (5/98)

NRI=Non-responder imputation.

Study Design:

UltIMMa-1 (N=506) and UltIMMa-2 (N=491) were replicate phase 3, randomized, double-blind, placebo- and active-controlled studies to evaluate the efficacy and safety of SKYRIZI (150 mg) vs placebo over 16 weeks and biologic active control (45 mg or 90 mg, based on screening weight) over 52 weeks in adult patients with moderate to severe plaque psoriasis. Patients received SKYRIZI 150 mg at Week 0, Week 4, and every 12 weeks thereafter.1,3

VIEW STUDY DESIGN AND BASELINE CHARACTERISTICS
PASI 90 PASI 90
PASI 100 PASI 100

In Part A of IMMvent,
a 2-part, Phase 3 study of patients with Ps

SKYRIZI DEMONSTRATED SUPERIOR RATES OF PASI 90 VS HUMIRA® (adalimumab) AT WEEK 162

72% OF SKYRIZI PATIENTS WITH Ps ACHIEVED PASI 90 VS 47% OF HUMIRA PATIENTS (NRI)2

WEEK 16 RESULTS (PART A)

72% of SKYRIZI® patients achieved PASI 90 vs 47% of HUMIRA® patients at week 16. 72% of SKYRIZI® patients achieved PASI 90 vs 47% of HUMIRA® patients at week 16. 72% of SKYRIZI® patients achieved PASI 90 vs 47% of HUMIRA® patients at week 16.

 

Part A Co-Primary Endpoints: PASI 90 and sPGA 0/1 at Week 16

STUDY DESIGN:

IMMvent was a Phase 3, randomized, double-blind, double-dummy, active-controlled study to evaluate the efficacy and safety of SKYRIZI (150 mg) compared to HUMIRA in adult patients with moderate to severe plaque psoriasis over 44 weeks.2

In Part A of the study, patients were randomized 1:1 to either SKYRIZI (150 mg) at Weeks 0 and 4, and every 12 weeks thereafter, or HUMIRA at an initial dose of 80 mg followed by 40 mg every other week starting 1 week after the initial dose. At Week 16, in Part B, patients taking HUMIRA with a PASI score of ≥50 but <90 were re-randomized 1:1 to either receive SKYRIZI (150 mg) at Weeks 16, 20, and 32, or continue HUMIRA. Patients who continued SKYRIZI in Part B remained on every-12-week dosing.2

VIEW STUDY DESIGN AND BASELINE CHARACTERISTICS

NRI=Non-responder imputation.

In Part B, HUMIRA patients who achieved PASI 50 to <90 were re-randomized 1:1

3x MORE PATIENTS ACHIEVED PASI 90 AFTER SWITCHING TO SKYRIZI THAN THOSE WHO REMAINED ON HUMIRA® (adalimumab)2

66% OF SKYRIZI PATIENTS WITH Ps ACHIEVED PASI 90 VS 21% OF HUMIRA PATIENTS (NRI)2

WEEK 44 RESULTS (PART B)

66% of SKYRIZI® patients achieved PASI 90 vs 21% of HUMIRA® patients at week 44. 66% of SKYRIZI® patients achieved PASI 90 vs 21% of HUMIRA® patients at week 44. 66% of SKYRIZI® patients achieved PASI 90 vs 21% of HUMIRA® patients at week 44.

*P<0.0001

 

Part B Primary Endpoint: PASI 90 at Week 44

STUDY DESIGN:

IMMvent was a Phase 3, randomized, double-blind, double-dummy, active-controlled study to evaluate the efficacy and safety of SKYRIZI (150 mg) compared to HUMIRA in adult patients with moderate to severe plaque psoriasis over 44 weeks.2

In Part A of the study, patients were randomized 1:1 to either SKYRIZI (150 mg) at Weeks 0 and 4, and every 12 weeks thereafter, or HUMIRA at an initial dose of 80 mg followed by 40 mg every other week starting 1 week after the initial dose. At Week 16, in Part B, patients taking HUMIRA with a PASI score of ≥50 but <90 were re-randomized 1:1 to either receive SKYRIZI (150 mg) at Weeks 16, 20, and 32, or continue HUMIRA. Patients who continued SKYRIZI in Part B remained on every-12-week dosing.2

VIEW STUDY DESIGN AND BASELINE CHARACTERISTICS

NRI=Non-responder imputation.

Click to see HUMIRA® (adalimumab)

Indication and Important Safety Information, including BOXED WARNING for Serious Infections and Malignancy.

See Full Prescribing Information
VIEW PASI 100 DATA

In Part A of IMMvent,
a 2-part, Phase 3 study of patients with Ps

SKYRIZI DEMONSTRATED SUPERIOR RATES OF PASI 100 VS HUMIRA® (adalimumab) AT WEEK 162

40% OF SKYRIZI PATIENTS WITH Ps ACHIEVED COMPLETE CLEARANCE (PASI 100) VS 23% OF HUMIRA PATIENTS (NRI)2

WEEK 16 RESULTS (PART A)

40% of SKYRIZI® patients achieved PASI 100 vs 23% of HUMIRA® patients at week 16. 40% of SKYRIZI® patients achieved PASI 100 vs 23% of HUMIRA® patients at week 16. 40% of SKYRIZI® patients achieved PASI 100 vs 23% of HUMIRA® patients at week 16.

*P<0.0001

 

Part A Ranked Secondary Endpoints: PASI 75 and PASI 100 at Week 16

STUDY DESIGN:

IMMvent was a Phase 3, randomized, double-blind, double-dummy, active-controlled study to evaluate the efficacy and safety of SKYRIZI (150 mg) compared to HUMIRA in adult patients with moderate to severe plaque psoriasis over 44 weeks.2

In Part A of the study, patients were randomized 1:1 to either SKYRIZI (150 mg) at Weeks 0 and 4, and every 12 weeks thereafter, or HUMIRA at an initial dose of 80 mg followed by 40 mg every other week starting 1 week after the initial dose. At Week 16, in Part B, patients taking HUMIRA with a PASI score of ≥50 but <90 were re-randomized 1:1 to either receive SKYRIZI (150 mg) at Weeks 16, 20, and 32, or continue HUMIRA. Patients who continued SKYRIZI in Part B remained on every-12-week dosing.2

VIEW STUDY DESIGN AND BASELINE CHARACTERISTICS

NRI=Non-responder imputation.

In Part B, HUMIRA patients who achieved PASI 50 to <90 were re-randomized 1:1

MORE PATIENTS ACHIEVED PASI 100 AFTER SWITCHING TO SKYRIZI THAN THOSE WHO REMAINED ON HUMIRA® (adalimumab)2

40% OF SKYRIZI PATIENTS WITH Ps ACHIEVED Complete clearance (PASI 100) VS 7% OF HUMIRA PATIENTS (NRI)2

WEEK 44 RESULTS (PART B)

40% of SKYRIZI® patients achieved PASI 100 vs 7% of HUMIRA® patients at week 44.

*P<0.0001

 

Part B Ranked Secondary Endpoint: PASI 100 at Week 44

STUDY DESIGN:

IMMvent was a Phase 3, randomized, double-blind, double-dummy, active-controlled study to evaluate the efficacy and safety of SKYRIZI (150 mg) compared to HUMIRA in adult patients with moderate to severe plaque psoriasis over 44 weeks.2

In Part A of the study, patients were randomized 1:1 to either SKYRIZI (150 mg) at Weeks 0 and 4, and every 12 weeks thereafter, or HUMIRA at an initial dose of 80 mg followed by 40 mg every other week starting 1 week after the initial dose. At Week 16, in Part B, patients taking HUMIRA with a PASI score of ≥50 but <90 were re-randomized 1:1 to either receive SKYRIZI (150 mg) at Weeks 16, 20, and 32, or continue HUMIRA. Patients who continued SKYRIZI in Part B remained on every-12-week dosing.2

VIEW STUDY DESIGN AND BASELINE CHARACTERISTICS

NRI=Non-responder imputation.

Click to see HUMIRA® (adalimumab)

Indication and Important Safety Information, including BOXED WARNING for Serious Infections and Malignancy.

See Full Prescribing Information
VIEW PASI 90 DATA

Well-Studied Safety Profile

across 4 pivotal trials1

REVIEW SAFETY

4 DOSES PER YEAR

4 doses per year after 2 initiation doses at Weeks 0 and 4 (150 mg/dose)1

VIEW DOSING SCHEDULE